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Carfentanil, one of the most potent opioids known, has recently been reported as
a contaminant in street heroin in the United States and Europe, and is associated
with an increased number of life-threatening emergency department admissions and
deaths. Here, we report on the application of a novel in vitro opioid activity reporter
assay and a sensitive bioanalytical assay in the context of a fatal carfentanil intoxication,
revealing the highest carfentanil concentrations reported until now. A 21-year-old male
was found dead at home with a note stating that he had taken carfentanil with suicidal
intentions. A foil bag and plastic bag labeled “C.50” were found at the scene. These
bags were similar to a sample obtained by the Belgian Early Warning System on
Drugs from a German darknet shop and to those found in the context of a fatality in
Norway. Blood, urine and vitreous, obtained during autopsy, were screened with a newly
developed in vitro opioid activity reporter assay able to detect compounds based on
their µ-opioid receptor activity rather than their chemical structure. All extracts showed
strong opioid activity. Results were confirmed by a bioanalytical assay, which revealed
extremely high concentrations for carfentanil and norcarfentanil. It should be noted
that carfentanil concentrations are typically in pg/mL, but here they were 92 ng/mL in
blood, 2.8 ng/mL in urine, and 23 ng/mL in vitreous. The blood and vitreous contained
0.532 and 0.300 ng/mL norcarfentanil, respectively. No norcarfentanil was detected
in urine. This is the first report where a novel activity-based opioid screening assay
was successfully deployed in a forensic case. Confirmation and quantification using a
validated bioanalytical procedure revealed the, to our knowledge, highest carfentanil
concentrations reported in humans so far.
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INTRODUCTION
Carfentanil, a very potent derivative of the pharmaceutical opioid fentanyl, was developed in 1974
by Janssen Pharmaceutica (Van Bever et al., 1976). It is one of the most potent opioids known at
∼10,000 times the potency of morphine and ∼30–100 times the potency of fentanyl in the tail
withdrawal test in rats (Van Bever et al., 1976). Commercially, it is always sold in combination
with the µ-opioid antagonist naloxone due to its extreme toxicity in humans. Carfentanil is used
to immobilize large exotic wildlife and has been implicated in the 2002 Moscow theater hostage
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crisis (Wax et al., 2003; Riches et al., 2012). Recently, carfentanil
and other synthetic opioids have been reported as a contaminant
in street heroin in the United States and Europe, and have
been associated with an increased number of life-threatening
emergency department admissions and deaths (EMCDDA and
Europol, 2017; Papsun et al., 2017; Shanks and Behonick, 2017;
Shulman et al., 2017). Here, we report on the application of a
novel cell-based bioassay and a sensitive bioanalytical assay in the
context of a fatal carfentanil intoxication, in which we found the
highest carfentanil concentrations reported until now.
CASE PRESENTATION
A 21-year-old male was found dead at home along with a note
stating that he had taken carfentanil with suicidal intentions,
in addition notifying first responders that care should be taken,
given the potency of the compound. A foil bag and plastic bag
labeled “C.50” were found at the scene (Figure 1A), suggesting
that up to 50 mg of carfentanil may have been insuﬄated by
the decedent. Remarkably, during routine monitoring of new
psychoactive substances (NPSs) present on darknet websites by
the Belgian Early Warning System on Drugs, a carfentanil sample
was obtained with strikingly similar packaging and handwriting
as the packaging found on the scene of death in this toxicological
case (Figure 1B). A similar bag with identical labeling in similar
handwriting has also been reported in the context of a fatality in
Norway (Figure 1C), where the powder was apparently ordered
from a German darknet shop (Vevelstad and Drange, 2017).
Based on this information, the vendor (or primary source) is most
probably the same vendor as mentioned in other publications
(Marlin and Hoyte, 2017; Vevelstad and Drange, 2017).
A swab of the plastic bag tested positive for carfentanil via
GC–MS analysis. Biological matrices available were blood, urine
and vitreous. Routine toxicological analyses were performed
on peripheral blood and urine. This involved, in addition to
immunological screening by EMIT and ELISA, the use of
HPLC-diode-array detection (DAD) and GC–MS for screening
and quantification of drugs and headspace-GC-FID for the
determination of ethanol and other volatile compounds,
essentially following procedures described before (Stove et al.,
2013). GC–MS screening of blood and urine revealed the
presence of caffeine, theobromine, propranolol, sertraline, and
cannabinoids in non-toxic doses. Immuno-assay based screening
for fentanyl (Fentanyl Direct Elisa Kit, Immunalysis, Pomona,
CA, United States) was negative.
An additional opioid screening of the biological matrices was
done with a new in-house developed opioid activity reporter
assay. We recently reported on cell-based cannabinoid reporter
assays for the activity-based detection of synthetic cannabinoids
and their metabolites, demonstrating cannabinoid activity in
authentic urine and blood samples (Cannaert et al., 2017).
A similar bioassay using the µ-opioid receptor to screen for
opioid activity in bulk materials and biological samples was set
up and evaluated (Cannaert et al., 2018). The principle of the
bioassay is activity-based, using an in vitro cell system, in which
activation of the µ-opioid receptor leads to the recruitment of the
cytosolic β-arrestin 2 (βarr2) protein, which results in functional
complementation of a split NanoLuc luciferase, thereby restoring
luciferase activity. In the presence of the substrate furimazine, this
results in a bioluminescent signal, which can be read out with a
standard luminometer.
In practice, expression vectors encoding human µ-opioid
receptor or βarr2, fused via a flexible linker to the subunits
of NanoLuc luciferase (LgBiT or SmBiT), were generated using
standard molecular biology techniques, similar as in Cannaert
et al. (2016). These constructs, with addition of a G-protein
coupled receptor kinase 2, were used to transiently transfect
human embryonic kidney (HEK) 293T cells, which were seeded
in poly-D-lysine-coated 96-well plates at 5 × 104 cells/well and
incubated overnight before performing the assay. On the day
of the assay, the cells were washed twice with Opti-MEM R© I
reduced serum medium to remove any remaining fetal bovine
serum, and 90 µL of Opti-MEM R© I was added. The Nano-Glo
Live Cell reagent, a non-lytic detection reagent containing the
cell-permeable furimazine substrate, was prepared by diluting the
Nano-Glo Live Cell substrate 20× using Nano-Glo LCS Dilution
buffer, and 25 µL was added to each well. Subsequently, the plate
was placed in a GloMAX96 plate reader (Promega, Madison,
WI, United States). Luminescence was monitored during the
equilibration period until the signal stabilized (30 min). For
agonist experiments, we added 20 µl per well of test compounds,
present as 6.75× stocks in Opti-MEM R© I. Also for the analysis
of biological extracts, 20 µL was added per well. These extracts
were generated from 250 µL of matrix (blood, urine, or vitreous),
which was added to 1000 µL of ice-cold acetonitrile, followed
by shaking for 5 min at 1400 RPM and centrifuging for 20 min
at 20,000 g. After evaporation of 1 mL of supernatant under
nitrogen at 40◦C, the extract was reconstituted in 100 µl of Opti-
MEM R© I. The luminescence was continuously detected (105 or
120 min).
Application of carfentanil and fentanyl solutions on the opioid
activity reporter assay resulted in concentration-dependent
curves and EC50 (95% confidence interval profile likelihood)
values were determined for carfentanil [EC50 = 0.027 nM
(0.021–0.035)] and fentanyl [EC50 = 4.32 nM (2.43–7.83)] as
a measure of relative potency (Figure 2A). Although it is
difficult to compare EC50 values from different assays (due to
different experimental setups), our values are in line with those
found in literature. Feasel (2017) stated in his dissertation an
EC50 of 0.006 nM for carfentanil and 0.511 nM for fentanyl
(PerkinElmer R© LANCE Ultra cAMP Assay), which supports the
significantly stronger potency of carfetanil, as also found here.
Norcarfentanil, the major metabolite of carfentanil, was only
able to generate low opioid activity at a high concentration
(1 µM/326 ng/mL) (Figure 2A). All extracts from the three
matrices (blood, urine, and vitreous) showed very strong opioid
activity. Even application of 1 µL of urine sample from the
presented case (without any sample preparation) on the bioassay
was able to generate a clearly positive signal, easily distinguishable
from negative control blank urine, in the opioid activity reporter
assay (Figure 2B).
The screening results from the opioid activity reporter assay
were confirmed with an LC–MS/MS method for carfentanil and
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FIGURE 1 | (A) Foil bag found at the scene. (B) Foil bag obtained by the Belgian Early Warning System on Drugs. (C) Foil bag and plastic bag found in a fatality in
Norway [image used with kind permission of the National Criminal Investigation Service/Photo (Norway)] (Vevelstad and Drange, 2017).
FIGURE 2 | (A) µ-opioid receptor activation by fentanyl, carfentanil and norcarfentanil. (B) µ-opioid receptor activation of pure urine without sample preparation.
AUC, area under curve; RLU, relative light units.
norcarfentanil. To 250 µL sample (blood, urine, or vitreous),
10 µL of internal standard solution containing fentanyl-D5
and norcarfentanil-D5 (0.25 and 12.5 ng/mL, respectively) in
methanol were added. Sample processing was as described above,
except that reconstitution was with 55 µL acetonitrile, of which
50 µL were then mixed with 50 µL of mobile phase A (H2O
+ 0.1% HCOOH) in an autosampler vial with 100 µL insert.
For the analysis of carfentanil, the injection volume was 20 µL,
whereas for the determination of norcarfentanil, 10 µL were
injected. Chromatographic separation was achieved on a Kinetex
Biphenyl column (50 mm × 2.1 mm, 2.6 µm) (Phenomenex,
Utrecht, Netherlands) in a 3.7 min gradient using H2O + 0.1%
HCOOH and methanol + 0.1% HCOOH as mobile phases, at
a flow rate of 0.6 mL/min. The following gradient was used:
0–0.2 min: 5%B, 0.25–0.35 min: 5–30% B, 0.35–1.5 min: 30–95%
B, 1.5–2.5 min: 95% B, 2.5–2.51 min: 95–5% B, 2.51–3.7 min: 5%
B. A QTRAP 5500 mass spectrometer (SCIEX, Nieuwerkerk aan
den Ijssel, Netherlands) with positive electrospray ionization in
multiple reaction monitoring mode was used for detection. For
carfentanil, the following transitions were used: 395.2 > 246.1
[quantifier, declustering potential (DP): 70 V, collision energy
(CE): 27 eV, collision cell exit potential (CXP): 12 V] and
395.2 > 146.2 (qualifier, DP: 70 V, CE: 37 eV, CXP: 9 V). For
norcarfentanil, the transitions were 291.1> 142.2 (quantifier, DP:
74 V, CE: 22 eV, CXP: 7 V) and 291.1 > 146.2 (qualifier, DP: 74
V, CE: 37 eV, CXP: 10 V). For fentanyl-D5, 342.2 > 188.2 (DP:
110 V, CE: 32 eV, CXP: 10 V) was used. For norcarfentanil-D5, the
transition was 296.1> 151.1 (DP: 75 V, CE: 38 eV, CXP: 8 V). The
entrance potential was 10 V for all transitions; source temperature
was set to 600◦C, ion spray voltage to 2000 V, curtain gas to 35 psi,
gas 1 to 40 psi and gas 2 to 50 psi.
The method was validated in whole blood. Eight-point
calibration curves were set up for carfentanil (range: 0.0025–
2.5 ng/mL, linear regression with 1/x2 weighting) and
norcarfentanil (range: 0.025–25 ng/mL, linear regression with
1/x2 weighting). Quality control samples at 0.015/0.25 ng/mL for
carfentanil and at 0.15/2.5 ng/mL for norcarfentanil were run
in sixplicate on 4 days, yielding acceptable intra- and inter-run
imprecision (intra-run: <8.8%, inter-run: <14%) and bias
(< ±8.7%, n = 24 at two different concentrations). Matrix effects
were assessed at the two above-mentioned concentrations by
comparing the signal ratios of analyte to internal standard of
post-extraction-spiked samples with those of standards spiked
in neat injection solvent (n = 6). Matrix effects were 78% for
carfentanil and 118% for norcarfentanil. Extraction efficiency,
assessed by comparing the signal ratios of analyte to internal
standard of pre- versus post-extraction-spiked samples, was 66%
for carfentanil and 24% for norcarfentanil (n = 6, at the two
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above-mentioned concentrations). Also, autosampler stability
(change in concentration <9% for at least 3 days, n = 6,
two different concentrations), specificity and carry-over (none
within calibration range) were successfully evaluated. Dilution
integrity was checked by spiking blood and aqueous samples with
100 ng/mL carfentanil and norcarfentanil, then diluting 1:1000
with blank matrix (n = 6) and comparing relative peak areas
to control samples with 0.1 ng/mL (n = 6). Differences were
≤±13.5%.
The vitreous sample was quantified using a calibration curve
in ultra-pure water. The urine sample was quantified by standard
addition. To quantify carfentanil concentrations, blood and
vitreous samples had to be diluted 1:1000 with blank blood and
water, respectively, while the urine sample was diluted 1:100 with
blank urine. For norcarfentanil, undiluted samples were analyzed.
Carfentanil concentrations were 92 ng/mL in blood, 2.8 ng/mL
in urine, and 23 ng/mL in vitreous. The blood and vitreous
contained 0.532 and 0.300 ng/mL norcarfentanil, respectively.
No norcarfentanil was detected in urine. It should be noted that
carfentanil concentrations are typically in the sub-ng/mL range
(Papsun et al., 2017: 0.1–14 ng/mL, median: 0.38 ng/mL; Shanks
and Behonick, 2017: 0.0102–2 ng/mL, median: 0.0984 ng/mL;
Hikin et al., 2018: 0.09–4 ng/mL, median: 0.234 ng/mL).
DISCUSSION
Given the continued emergence of novel synthetic opioids, the
major disadvantage for their detection via immunoassays, GC–
MS and LC–MS/MS analysis is that the methods are often
targeted in nature or, for the latter two, limited by the availability
of pre-established mass spectral libraries. Here in this case,
the immunoassay for fentanyl did not pick up carfentanil, a
fentanyl analog, due to the lack of cross-reactivity. Therefore, an
alternative untargeted approach for the detection of (synthetic)
opioids, not directly based on the structure of the opioids, but on
their opioid activity, was applied. Such an approach may serve
as a first-line screening tool, complementing the conventional
analytical methods which are currently used.
The high ratio of carfentanil/norcarfentanil in blood and
vitreous and the absence of norcarfentanil in urine can be
explained by the presumably sudden death of the victim
caused by the massive overdose. The detected concentrations
of carfentanil are, to the best of our knowledge, the highest
ever reported in a human being. Other intoxications always
state sub-ng to low ng/mL levels of carfentanil (Müller et al.,
2017; Papsun et al., 2017; Shanks and Behonick, 2017; Swanson
et al., 2017; Elliott and Hernandez Lopez, 2018; Hikin et al.,
2018). In conclusion, this is the first report in which a novel
activity-based opioid screening assay was successfully deployed
in a forensic case, where confirmation and quantification using a
validated bioanalytical procedure revealed very high carfentanil
concentrations.
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